Antiproliferative effects of the CDK6 inhibitor PD0332991 and its effect on signaling networks in gastric cancer cells

Wang,Daguang; Sun,Yabin; Li,Wei; Ye,Fei; Zhang,Yang; Guo,Yuchen; Zhang,David  Y.; Suo,Jian

doi:10.3892/ijmm.2018.3460

Antiproliferative effects of the CDK6 inhibitor PD0332991 and its effect on signaling networks in gastric cancer cells

Authors:
- Daguang Wang
- Yabin Sun
- Wei Li
- Fei Ye
- Yang Zhang
- Yuchen Guo
- David Y. Zhang
- Jian Suo
View Affiliations

Affiliations: Department of Gastric and Colorectal Surgery, The First Hospital, Jilin University, Changchun, Jilin 130021, P.R. China, Department of Ophthalmology, The First Hospital, Jilin University, Changchun, Jilin 130021, P.R. China, Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
Published online on: February 6, 2018 https://doi.org/10.3892/ijmm.2018.3460
Pages: 2473-2484
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

PD0332991 (palbociclib/Ibrance®) is a cyclin-dependent kinase (CDK)4/6 inhibitor that has recently been approved for the treatment of estrogen receptor‑positive advanced breast cancer. The present study investigated the antiproliferative effects of PD0332991 on gastric cancer (GC) cells and the underlying molecular mechanisms. The activity of PD0332991 was tested in several GC cell lines, including AGS, KATO‑Ⅲ, NCI‑N87 and HS746T. Growth inhibitory activity of PD0332991, alone or in combination with fluorouracil (5‑FU), was measured by MTT assay. The effects of PD0332991 on cell cycle progression were analyzed by flow cytometry and western blotting. Protein pathway array and Ingenuity Pathway Analysis were used to identify signaling pathways that may mediate the antiproliferative effects of PD0332991. PD0332991 inhibited proliferation in a dose‑dependent manner and enhanced the activity of 5‑FU in all GC cell lines tested. Cells treated with PD0332991 exhibited cell cycle arrest in G1 phase of the cell cycle, whereas the number of cells in G2/M phase was decreased. PD0332991 also inhibited CDK6‑specific phosphorylation of retinoblastoma on Ser780, reduced the expression of cyclin D1, and induced expression of p53 and p27. Furthermore, 31 proteins were identified, the expression of which was significantly altered following treatment with PD0332991 in at least three cell lines. Pathway analysis indicated that the altered proteins were frequently associated with cell death, cell cycle and the molecular mechanism of cancer. The results of the present study indicated that PD0332991 may inhibit cell proliferation via modulation of the cell cycle, and may affect numerous oncogenic signaling pathways. Therefore, PD0332991 may be considered effective for the treatment of GC.

View Figures

View References

1	Carcas LP: Gastric cancer review. J Carcinog. 13:142014. View Article : Google Scholar
2	Thiel A and Ristimäki A: Targeted therapy in gastric cancer. APMIS. 123:365–372. 2015. View Article : Google Scholar : PubMed/NCBI
3	Hohenberger P and Gretschel S: Gastric cancer. Lancet. 362:305–315. 2003. View Article : Google Scholar : PubMed/NCBI
4	May P and May E: Twenty years of p53 research: Structural and functional aspects of the p53 protein. Oncogene. 18:7621–7636. 1999. View Article : Google Scholar
5	Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, Albassam M, Zheng X, Leopold WR, Pryer NK, et al: Specific inhibition of cyclin-dependent kinase 4/6 by PD0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 3:1427–1438. 2004.PubMed/NCBI
6	Toogood PL, Harvey PJ, Repine JT, Sheehan DJ, VanderWel SN, Zhou H, Keller PR, McNamara DJ, Sherry D, Zhu T, et al: Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. J Med Chem. 48:2388–2406. 2005. View Article : Google Scholar : PubMed/NCBI
7	VanderWel SN, Harvey PJ, McNamara DJ, Repine JT, Keller PR, Quin J III, Booth RJ, Elliott WL, Dobrusin EM, Fry DW, et al: Pyrido[2,3-d]pyrimidin-7-ones as specific inhibitors of cyclin-dependent kinase 4. J Med Chem. 48:2371–2387. 2005. View Article : Google Scholar : PubMed/NCBI
8	Foo M and Leong T: Adjuvant therapy for gastric cancer: Current and future directions. World J Gastroenterol. 20:13718–13727. 2014. View Article : Google Scholar : PubMed/NCBI
9	Kanat O and O'Neil BH: Metastatic gastric cancer treatment: A little slow but worthy progress. Med Oncol. 30:4642013. View Article : Google Scholar : PubMed/NCBI
10	Sherr CJ and Roberts JM: CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev. 13:1501–1512. 1999. View Article : Google Scholar : PubMed/NCBI
11	Lee SR, Shin JW, Kim HO, Son BH, Yoo CH and Shin JH: Determining the effect of transforming growth factor-β1 on cdk4 and p27 in gastric cancer and cholangiocarcinoma. Oncol Lett. 5:694–698. 2013. View Article : Google Scholar : PubMed/NCBI
12	Motohashi M, Wakui S, Muto T, Suzuki Y, Shirai M, Takahashi H and Hano H: Cyclin D1/cdk4, estrogen receptors α and β, in N-methyl-N′-nitro-N-nitrosoguanidine-induced rat gastric carcinogenesis: Immunohistochemical study. J Toxicol Sci. 36:373–378. 2011. View Article : Google Scholar : PubMed/NCBI
13	Takano Y, Kato Y, van Diest PJ, Masuda M, Mitomi H and Okayasu I: Cyclin D2 overexpression and lack of p27 correlate positively and cyclin E inversely with a poor prognosis in gastric cancer cases. Am J Pathol. 156:585–594. 2000. View Article : Google Scholar : PubMed/NCBI
14	Dhillon S: Palbociclib: First global approval. Drugs. 75:543–551. 2015. View Article : Google Scholar : PubMed/NCBI
15	Carey LA and Perou CM: Palbociclib - taking breast-cancer cells out of gear. N Engl J Med. 373:273–274. 2015. View Article : Google Scholar : PubMed/NCBI
16	Dukelow T, Kishan D, Khasraw M and Murphy CG: CDK4/6 inhibitors in breast cancer. Anticancer Drugs. 26:797–806. 2015. View Article : Google Scholar : PubMed/NCBI
17	Morikawa A and Henry L: Palbociclib for the treatment of estrogen receptor-positive, HER2-negative metastatic breast cancer. Clin Cancer Res. 21:3591–3596. 2015. View Article : Google Scholar : PubMed/NCBI
18	Young MR, Li JJ, Rincón M, Flavell RA, Sathyanarayana BK, Hunziker R and Colburn N: Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion. Proc Natl Acad Sci USA. 96:9827–9832. 1999. View Article : Google Scholar : PubMed/NCBI
19	Eferl R, Ricci R, Kenner L, Zenz R, David JP, Rath M and Wagner EF: Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53. Cell. 112:181–192. 2003. View Article : Google Scholar : PubMed/NCBI
20	Behrens A, Sibilia M, David JP, Möhle-Steinlein U, Tronche F, Schütz G and Wagner EF: Impaired postnatal hepatocyte proliferation and liver regeneration in mice lacking c-jun in the liver. EMBO J. 21:1782–1790. 2002. View Article : Google Scholar : PubMed/NCBI
21	Schreiber M, Kolbus A, Piu F, Szabowski A, Möhle-Steinlein U, Tian J, Karin M, Angel P and Wagner EF: Control of cell cycle progression by c-Jun is p53 dependent. Genes Dev. 13:607–619. 1999. View Article : Google Scholar : PubMed/NCBI
22	Wisdom R, Johnson RS and Moore C: c-Jun regulates cell cycle progression and apoptosis by distinct mechanisms. EMBO J. 18:188–197. 1999. View Article : Google Scholar : PubMed/NCBI
23	Behrens A, Sibilia M and Wagner EF: Amino-terminal phosphorylation of c-Jun regulates stress-induced apoptosis and cellular proliferation. Nat Genet. 21:326–329. 1999. View Article : Google Scholar : PubMed/NCBI
24	Mechta F, Lallemand D, Pfarr CM and Yaniv M: Transformation by ras modifies AP1 composition and activity. Oncogene. 14:837–847. 1997. View Article : Google Scholar : PubMed/NCBI
25	Reya T and Clevers H: Wnt signalling in stem cells and cancer. Nature. 434:843–850. 2005. View Article : Google Scholar : PubMed/NCBI
26	Amelio I and Melino G: The p53 family and the hypoxia-inducible factors (HIFs): Determinants of cancer progression. Trends Biochem Sci. 40:425–434. 2015. View Article : Google Scholar : PubMed/NCBI
27	Baker SJ, Markowitz S, Fearon ER, Willson JK and Vogelstein B: Suppression of human colorectal carcinoma cell growth by wild-type p53. Science. 249:912–915. 1990. View Article : Google Scholar : PubMed/NCBI
28	Diller L, Kassel J, Nelson CE, Gryka MA, Litwak G, Gebhardt M, Bressac B, Ozturk M, Baker SJ and Vogelstein B: p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol. 10:5772–5781. 1990. View Article : Google Scholar : PubMed/NCBI
29	Martinez J, Georgoff I, Martinez J and Levine AJ: Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein. Genes Dev. 5:151–159. 1991. View Article : Google Scholar : PubMed/NCBI
30	Steelman LS, Stadelman KM, Chappell WH, Horn S, Bäsecke J, Cervello M, Nicoletti F, Libra M, Stivala F, Martelli AM, et al: Akt as a therapeutic target in cancer. Expert Opin Ther Targets. 12:1139–1165. 2008. View Article : Google Scholar : PubMed/NCBI
31	Fraser M, Leung BM, Yan X, Dan HC, Cheng JQ and Tsang BK: p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells. Cancer Res. 63:7081–7088. 2003.PubMed/NCBI